苏尼替尼

规格或纯度: 99%

CAS编号: 557795-19-4
分子式: C₂₂H₂₇FN₄O₂
分子量: 398.47
PubChem编号: 5329102

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
S126061-250mg	250mg	现货
S126061-1g	1g	现货
S126061-5g	5g	现货
S126061-25g	25g	现货

查看相关系列

fibroblast growth factor receptor 1 Inhibitor fms related receptor tyrosine kinase 3 Inhibitor fms related receptor tyrosine kinase 4 Inhibitor kinase insert domain receptor Inhibitor KIT proto-oncogene，receptor tyrosine kinase Inhibitor platelet derived growth factor receptor beta Inhibitor ret proto-oncogene Inhibitor

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本描述

别名	舒尼替尼
英文别名	1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-\|D08552\|C22H27FN4O2\|N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide\|SCHEMBL510
规格或纯度	99%
英文名称	Sunitinib
生化机理	IC50 Value: 2 nM (PDGFRβ); 80 nM (VEGFR2) [1] Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. in vitro: Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively [2]. SU11248 also has potent activity against wild-type FLT3 (FLT3-WT), FLT3-ITD, and FLT3 activation loop (FLT3-Asp835) mutants in phosphorylation as
储存温度	-20°C储存
运输条件	超低温冰袋运输
备注	100mg卖完停产，不再备货
产品介绍	Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

名称和标识符

PubChem SID	488195369
IUPAC Name	N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
INCHI	InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
InChi Key	WINHZLLDWRZWRT-ATVHPVEESA-N
Canonical SMILES	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
Isomeric SMILES	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C
PubChem CID	5329102
UN Number	2811
Packing Group	III
分子量	398.47

数据库链接

CAS Registry No.	557795-19-4
DrugBank Ligand	DB01268
Wikipedia	Sunitinib
DiscoveRx TREEspot	Sunitinib\|
PubChem CID	5329102
ChEMBL Ligand	CHEMBL535
RCSB PDB Ligand	B49
PEP	sunitinib
Reactome Reaction	R-HSA-9674398, R-HSA-9702510, R-HSA-9695831, R-HSA-9669854, R-HSA-9669900, R-HSA-9674430, R-HSA-9674095, R-HSA-9702629, R-HSA-9669878
Reactome Drug	R-ALL-9669720
DrugCentral Ligand	2544
PubChem SID	488195369

CAS Registry No.

557795-19-4

DrugBank Ligand

DB01268

Wikipedia

Sunitinib

DiscoveRx TREEspot

Sunitinib|

PubChem CID

5329102

ChEMBL Ligand

CHEMBL535

RCSB PDB Ligand

B49

PEP

sunitinib

Reactome Reaction

R-HSA-9674398, R-HSA-9702510, R-HSA-9695831, R-HSA-9669854, R-HSA-9669900, R-HSA-9674430, R-HSA-9674095, R-HSA-9702629, R-HSA-9669878

Reactome Drug

R-ALL-9669720

DrugCentral Ligand

2544

PubChem SID

488195369

溶解性	25°C: DMSO

安全和危险性（GHS）

象形图	Toxic
信号词	Danger
危险声明	H372: Causes damage to organs through prolonged or repeated exposure H360: May damage fertility or the unborn child
预防措施声明	P280,P405,P501,P264,P260,P201,P308+P313,P270,P202

相关文档

产品问答

登录提交问题

查看全部

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB et al.. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.. Clin Cancer Res, 9 (1): (327-37). [PMID:12538485]
2. Khanwelkar RR, Chen GS, Wang HC, Yu CW, Huang CH, Lee O, Chen CH, Hwang CS, Ko CH, Chou NT et al.. (2010) Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.. Bioorg Med Chem, 18 (13): (4674-86). [PMID:20570526]

苏尼替尼

库存信息

库存信息

库存信息

库存信息

基本描述

名称和标识符

数据库链接

化学和物理性质

安全和危险性（GHS）

质检证书(COA)

质检报告(COA)

相关文档

质检报告COA

可替换产品

产品问答

产品问答

参考文献